Close Menu

NEW YORK (GenomeWeb) – Fresh off a $225,000 grant from the Mark Foundation for Cancer Research, a group led by Weill Cornell Medicine and the New York Genome Center researchers has developed a whole-genome sequencing assay to track cumulative patterns of genetic mutations in a patient's bloodstream. The researchers believe the assay could eventually be used to assess minimal residual disease status in patients after tumor resection.

The team has also begun to commercialize the test to look at cell-free DNA (cfDNA) in patients as part of a spinout led by Weill Cornell and NYGC.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Oct
03

This webinar will provide an overview of how an international reference laboratory has implemented an automated next-generation sequencing workflow with custom panels for analyzing cancer samples.

Oct
24

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.